Lupin Pharmaceuticals has received approval for its Irbesartan tablets, used for treating hypertension, from US Food and Drugs Administration (USFDA).
The tablets are available in 75-300 mg strengths and are the AB-rated generic equivalent of Sanofi Aventis's Avapro tablets, Lupin said in a statement issued here.
Irbesartan is indicated for the treatment of hypertension and nephropathy in type II diabetic patients, it added.
Avapro tablets had annual US sales of about $400.7 million in June, as per the IMS health sales data.
Lupin is the fifth largest generic player in the US with 5.1% market share by prescriptions.
The company said it is also the fastest growing, top 10 pharma player in India, Japan and South Africa.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app